The main objective of this study was to increase complete response rate with undetectable minimal 46 residual disease three months after treatment and was previously published. Peripheral blood mononuclear cells (PBMCs) were purified from peripheral blood samples of 68 arm 50 B patients with CLL using Ficoll-Hypaque density gradients (Eurobio, Courtaboeuf, France).
3 PBMCs 51 were resuspended (9 x 10 6 cells/mL) in medium (RPMI 1640 media (Biotech GmbH, Aidenbach, 52
Germany) containing 10% fetal calf serum (Eurobio, Courtaboeuf, France), 2 mM L-glutamine 53 (Eurobio, Courtaboeuf, France), 100 U/mL penicillin, 100 µg/mL streptomycin, and 2.5 µg/mL 54 amphotericin (all antibiotics from Tebu-bio, Le Perray-en-Yvelines, France). Clonal activation of 55 lymphocytes B (LB) were stimulated with CpG (ODN 2006, 10 µg/mL; InvivoGen, San Diego, USA), 56 CD40L (50 ng/mL; R&D Systems, Minneapolis, MN, USA) and anti-polyHistidine (500 ng/mL; R&D 57 Systems, Minneapolis, MN, USA) for 48 h at 37°C in a 5% CO 2 -95% air humidified atmosphere. PMA 58
(50 ng/mL; Sigma-Aldrich, Saint Louis, MO, USA) and ionomycin (1 µg/mL; Sigma-Aldrich, Saint Louis, 59
MO, USA) were added on cells to stimulate IL-10 production. After 4 h at 37°C in a 5% CO 2 -95% air 60 humidified atmosphere, brefeldin A (1 X solution/mL; BioLegend, San Diego, CA, USA) blocked IL-10 61 secretion to determine B10pro + B10 cell population. 
